HRP20231207T1 - Pripravak koji sadrži ibrutinib - Google Patents

Pripravak koji sadrži ibrutinib Download PDF

Info

Publication number
HRP20231207T1
HRP20231207T1 HRP20231207TT HRP20231207T HRP20231207T1 HR P20231207 T1 HRP20231207 T1 HR P20231207T1 HR P20231207T T HRP20231207T T HR P20231207TT HR P20231207 T HRP20231207 T HR P20231207T HR P20231207 T1 HRP20231207 T1 HR P20231207T1
Authority
HR
Croatia
Prior art keywords
sodium
pharmaceutical preparation
mixing
lymphoma
preparation according
Prior art date
Application number
HRP20231207TT
Other languages
English (en)
Inventor
Dilip Gole
Manish Kumar Gupta
Kaustubh TAMBWEKAR
Binuraj Krishnan NAIR
Maristella BERNINI
Sabine INGHELBRECHT
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20231207(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HRP20231207T1 publication Critical patent/HRP20231207T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (14)

1. Farmaceutski pripravak, naznačen time, da sadrži: (a) 30 do 80 mg/mL Ibrutiniba; (b) 12 do 15 mg/mL mikrokristalne celuloze i karboksimetilceluloze natrij; (c) 0,5 do 3 mg/mL hidroksipropilmetilceluloze; (d) 1,4 do 1,7 mg/mL monohidrata limunske kiseline; (e) 1,4 mg/mL dinatrij hidrogen fosfata; (f) 0,5 do 1,5 mg/mL sukraloze; (g) 1 do 1,5 mg/mL natrij metil parahidroksibenzoata; (h) 0,5 do 0,7 mg/mL natrij etil parahidroksibenzoata; (i) koncentriranu klorovodičnu kiselinu; (j) natrijev hidroksid; i (k) vodu.
2. Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time, da sadrži 30 do 50 mg/mL Ibrutiniba, ili poželjno 60 do 80 mg/mL Ibrutiniba.
3. Farmaceutski pripravak prema patentnom zahtjevu 1 ili 2, naznačen time, da sadrži 13 do 15 mg/mL mikrokristalne celuloze i karboksimetilceluloze natrij, ili poželjno 12 do 14 mg/mL mikrokristalne celuloze i karboksimetilceluloze natrij.
4. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da sadrži 2 do 3 mg/mL hidroksipropilmetilceluloze, ili poželjno 0,5 do 1,5 mg/mL hidroksipropilmetilceluloze.
5. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da sadrži dovoljnu količinu koncentrirane klorovodične kiseline ili natrijevog hidroksida za održavanje pH na oko 6.
6. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da sadrži dovoljnu količinu vode kako bi se osigurao ukupni volumen od 1 mL.
7. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je tekuća suspenzija.
8. Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time, da sadrži: (i) oko 70 mg/mL Ibrutiniba; (ii) oko 13 mg/mL mikrokristalne celuloze i karboksimetilceluloze natrij; (iii) oko 2,5 mg/mL hidroksipropilmetilceluloze; (iv) oko 1,5 mg/mL monohidrata limunske kiseline; (v) oko 1,4 mg/mL dinatrij hidrogen fosfata; (vi) oko 1 mg/mL sukraloze; (vii) oko 1 mg/mL natrij metil parahidroksibenzoata; i (viii) oko 0,6 mg/mL natrij etil parahidroksibenzoata.
9. Farmaceutski pripravak prema patentnom zahtjevu 1, naznačen time, da sadrži: (i) oko 40 mg/mL Ibrutiniba; (ii) oko 14 mg/mL mikrokristalne celuloze i karboksimetilceluloze natrij; (iii) oko 1 mg/mL hidroksipropilmetil celuloze; (iv) oko 1,6 mg/mL monohidrata limunske kiseline; (v) oko 1,4 mg/mL dinatrij hidrogen fosfata; (vi) oko 0,5 mg/mL sukraloze; (vii) oko 1,4 mg/mL natrij metil parahidroksibenzoata; i (viii) oko 0,7 mg/mL natrij etil parahidroksibenzoata.
10. Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je za uporabu u postupku za liječenje proliferativnog poremećaja B stanica.
11. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 10, naznačen time, da navedeni proliferativni poremećaj B stanica je ne-Hodgkinov limfom, Waldenstromova makroglobulinemija, mijelom stanica plazme, ili kronična limfocitna leukemija, opcionalno gdje ne-Hodgkinov limfom je difuzni veliki limfom B stanica, folikularni limfom, limfom plaštenih stanica ili Burkittov limfom, istaknuto limfom, ili istaknuto leukemija.
12. Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da je za uporabu u postupku za liječenje limfoma plaštenih stanica kod pojedinca koji je već primio najmanje jednu prethodnu terapiju za limfom plaštenih stanica, pri čemu postupak obuhvaća davanje farmaceutskog pripravka jednom na dan.
13. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 10 do 12, naznačen time, da je farmaceutski pripravak raspršen u hrani kao blaga hrana.
14. Postupak za proizvodnju pripravka prema patentnom zahtjevu 1, naznačen time, da spomenuti postupak obuhvaća: (a) miješanje vode, mikrokristalne celuloze kroskarmeloze natrij; (b) miješanje vode i s hidroksipropilmetilcelulozom; (c) miješanje proizvoda iz koraka (b) s Ibrutinibom; (d) miješanje proizvoda iz koraka (a) i (c); (e) miješanje proizvoda iz koraka (d) sa sukralozom; (f) miješanje proizvoda iz koraka (e) s natrij metil parahidroksibenzoatom i natrij etil parahidroksibenzoatom; (g) miješanje proizvoda iz koraka (f) s monohidratom limunske kiseline; i (h) miješanje proizvoda iz koraka (g) s bezvodnim dinatrij hidrogen fosfatom.
HRP20231207TT 2015-04-06 2016-04-06 Pripravak koji sadrži ibrutinib HRP20231207T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562143659P 2015-04-06 2015-04-06
EP21161828.5A EP3892302B8 (en) 2015-04-06 2016-04-06 Compositions containing ibrutinib

Publications (1)

Publication Number Publication Date
HRP20231207T1 true HRP20231207T1 (hr) 2024-01-19

Family

ID=55806788

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231207TT HRP20231207T1 (hr) 2015-04-06 2016-04-06 Pripravak koji sadrži ibrutinib

Country Status (28)

Country Link
US (5) US20160287594A1 (hr)
EP (3) EP4272835A3 (hr)
JP (3) JP2018513852A (hr)
KR (2) KR102632745B1 (hr)
CN (2) CN107530293A (hr)
AU (3) AU2016246669B2 (hr)
CA (1) CA2981601A1 (hr)
CL (1) CL2017002512A1 (hr)
DK (1) DK3892302T3 (hr)
EA (1) EA033992B1 (hr)
ES (1) ES2964472T3 (hr)
FI (1) FI3892302T3 (hr)
HK (1) HK1250925A1 (hr)
HR (1) HRP20231207T1 (hr)
HU (1) HUE063751T2 (hr)
IL (2) IL295941A (hr)
LT (1) LT3892302T (hr)
MA (2) MA54411B1 (hr)
MD (1) MD3892302T2 (hr)
MX (2) MX2017012822A (hr)
PH (1) PH12017501811A1 (hr)
PL (1) PL3892302T3 (hr)
PT (1) PT3892302T (hr)
RS (1) RS64653B1 (hr)
SG (2) SG10202103458QA (hr)
SI (1) SI3892302T1 (hr)
UA (1) UA125681C2 (hr)
WO (1) WO2016164404A1 (hr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3218491A1 (en) 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
MX2017001671A (es) 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
BR122023020985A2 (pt) 2015-03-03 2023-12-26 Pharmacyclics Llc Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
CN108653231A (zh) * 2017-04-01 2018-10-16 北京赛林泰医药技术有限公司 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
CA3076907A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
CA3089537A1 (en) 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
KR20190122561A (ko) * 2018-04-21 2019-10-30 류형준 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물
WO2019238904A1 (en) 2018-06-15 2019-12-19 Janssen Pharmaceutica Nv Formulations/compositions comprising ibrutinib
EP3836899A2 (en) * 2018-08-18 2021-06-23 FTF Pharma Private Limited Chemotherapeutic pharmaceutical suspension for oral dosage
GB2591396B (en) * 2018-08-18 2023-06-07 Ftf Pharma Private Ltd Pharmaceutical suspension for oral dosage
KR102198502B1 (ko) * 2018-09-16 2021-01-05 류형준 인체의 림프순환 개선을 위한 식품 조성물
CN113164782A (zh) * 2018-11-30 2021-07-23 詹森生物科技公司 治疗滤泡型淋巴瘤的方法
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
KR102251435B1 (ko) * 2020-11-09 2021-05-11 류형준 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물
WO2022260667A1 (en) * 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Oral dosage forms of ibrutinib
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0610431A2 (pt) * 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico
DK2081435T3 (en) 2006-09-22 2016-08-15 Pharmacyclics Llc INHIBITORS OF BRUTON'S TYROSINKINASE
US8003309B2 (en) 2008-01-16 2011-08-23 International Business Machines Corporation Photoresist compositions and methods of use in high index immersion lithography
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
CN110801454A (zh) * 2011-10-19 2020-02-18 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的用途
CA3218491A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics Llc Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014004707A1 (en) * 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
EP3603715B1 (en) 2013-03-14 2021-03-03 Fisher & Paykel Healthcare Limited Catheter mount with suction port
ES2709509T3 (es) * 2013-08-12 2019-04-16 Pharmacyclics Llc Procedimientos para el tratamiento de cáncer amplificado por HER2
US9617432B2 (en) * 2013-08-12 2017-04-11 The Yokohama Rubber Co., Ltd. Primer composition
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
MX2017001671A (es) 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
CN104523695A (zh) * 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN104407067B (zh) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 依鲁替尼及其异构体的检测方法
BR122023020985A2 (pt) * 2015-03-03 2023-12-26 Pharmacyclics Llc Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton

Also Published As

Publication number Publication date
SG10202103458QA (en) 2021-05-28
EA033992B1 (ru) 2019-12-17
SG11201707989PA (en) 2017-10-30
WO2016164404A1 (en) 2016-10-13
JP7438178B2 (ja) 2024-02-26
US20160287594A1 (en) 2016-10-06
SI3892302T1 (sl) 2023-11-30
US20220211713A1 (en) 2022-07-07
EP3892302B1 (en) 2023-09-06
EP3280446A1 (en) 2018-02-14
EP3892302A1 (en) 2021-10-13
PL3892302T3 (pl) 2024-03-11
EP4272835A2 (en) 2023-11-08
MA54411B1 (fr) 2023-11-30
AU2021250925B2 (en) 2023-11-16
MA41901A (fr) 2021-04-14
AU2021250925A1 (en) 2021-11-11
US20200171036A1 (en) 2020-06-04
KR20240013859A (ko) 2024-01-30
EA201792224A1 (ru) 2018-06-29
DK3892302T3 (da) 2023-11-13
RS64653B1 (sr) 2023-10-31
IL254695A0 (en) 2017-11-30
AU2016246669B2 (en) 2021-07-15
PT3892302T (pt) 2023-11-15
PH12017501811A1 (en) 2018-04-23
KR102632745B1 (ko) 2024-02-01
MD3892302T2 (ro) 2024-03-31
JP2022031690A (ja) 2022-02-22
LT3892302T (lt) 2023-11-10
CL2017002512A1 (es) 2018-03-16
IL295941A (en) 2022-10-01
MX2017012822A (es) 2018-06-13
HK1250925A1 (zh) 2019-01-18
JP2018513852A (ja) 2018-05-31
UA125681C2 (uk) 2022-05-18
MA54411A (fr) 2021-10-13
CA2981601A1 (en) 2016-10-13
JP2024026087A (ja) 2024-02-28
KR20170134582A (ko) 2017-12-06
IL254695B2 (en) 2023-02-01
AU2024200883A1 (en) 2024-02-29
US20170252344A1 (en) 2017-09-07
AU2016246669A1 (en) 2017-10-12
CN113546054A (zh) 2021-10-26
HUE063751T2 (hu) 2024-01-28
US20230263804A1 (en) 2023-08-24
FI3892302T3 (fi) 2023-11-03
BR112017021325A2 (pt) 2018-06-26
EP3892302B8 (en) 2023-10-18
EP4272835A3 (en) 2023-12-20
MX2021015250A (es) 2022-01-24
CN107530293A (zh) 2018-01-02
ES2964472T3 (es) 2024-04-08
IL254695B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
HRP20231207T1 (hr) Pripravak koji sadrži ibrutinib
JP2018513852A5 (hr)
MY162175A (en) Aqueous drug delivery system
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2015012109A (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso.
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
EA033291B1 (ru) Единица дозирования, содержащая рамиприл и бисопролола гемифумарат, способ ее получения и способ лечения гипертензии
EA200901591A1 (ru) Фармацевтические композиции производных s-алкилизотиоурония с маскированным вкусом
NZ707033A (en) Dispersible nimorazole tablet
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
MX2011011879A (es) Uso de las betaxantinas y sus derivados para preparar un medicamento para el tratamiento de la prediabetes y diabetes.
RU2012115039A (ru) Способ лечения хронического эндометрита
MY196892A (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
MX2011011880A (es) Uso de la betanidina, isobetanidina y sus derivados para preparar un medicamento para el tratamiento de la prediabetes y diabetes.
SA515360445B1 (ar) قرص قابل للتشتيت
GR1006279B (el) Ποσιμα διαλυματα αλατων γλυκοζαμινης ή θειικης χονδροϊτινης σε συνδυασμο με υαλουρονικο νατριο
DK201270714A (en) Dispersible tablet
GR1008112B (el) Φαρμακευτικο σκευασμα περιεχον εναν εκλεκτικο αγωνιστη των υποδοχεων της σεροτονινης και μεθοδος για την παρασκευη αυτου
BG2223U1 (bg) Антипаразитен шампоан
UA88225U (uk) Спосіб одержання фармацевтичного продукту, що містить налбуфін
UA75754U (uk) Спосіб лікування хворих на непроліферативну діабетичну ретинопатію
RU2014142874A (ru) Способ лечения похмельного синдрома у лиц, не относящихся к больным алкоголизмом
GR1006234B (el) Ποσιμα διαλυματα τρυγικης λεβοκαρνιτινης μετα απο ανασυσταση